$2.59
8.16% today
Nasdaq, Apr 01, 07:19 pm CET
ISIN
US82686Q1013
Symbol
SLN

Silence Therapeutics Plc - ADR Stock price

$2.82
-1.68 37.33% 1M
-15.36 84.49% 6M
-4.06 59.01% YTD
-18.88 87.00% 1Y
-16.18 85.16% 3Y
-16.68 85.54% 5Y
-16.68 85.54% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.62 18.02%
ISIN
US82686Q1013
Symbol
SLN
Sector
Industry

Key metrics

Market capitalization $133.17m
Enterprise Value $-39.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.75
EV/Sales (TTM) EV/Sales -1.93
P/S ratio (TTM) P/S ratio 6.47
P/B ratio (TTM) P/B ratio 1.05
Revenue growth (TTM) Revenue growth -40.10%
Revenue (TTM) Revenue $20.57m
EBIT (operating result TTM) EBIT $-74.19m
Free Cash Flow (TTM) Free Cash Flow $-52.56m
Cash position $173.02m
EPS (TTM) EPS $-1.67
P/E forward negative
P/S forward 3.72
EV/Sales forward negative
Short interest 4.75%
Show more

Is Silence Therapeutics Plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Silence Therapeutics Plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

5x Buy
83%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Silence Therapeutics Plc - ADR forecast:

Buy
83%
Sell
17%

Financial data from Silence Therapeutics Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
21 21
40% 40%
100%
- Direct Costs 11 11
29% 29%
55%
9.16 9.16
50% 50%
45%
- Selling and Administrative Expenses 25 25
6% 6%
122%
- Research and Development Expense 58 58
11% 11%
281%
-74 -74
28% 28%
-358%
- Depreciation and Amortization 0.60 0.60
5% 5%
3%
EBIT (Operating Income) EBIT -74 -74
28% 28%
-361%
Net Profit -75 -75
44% 44%
-365%

In millions USD.

Don't miss a Thing! We will send you all news about Silence Therapeutics Plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silence Therapeutics Plc - ADR Stock News

Neutral
Business Wire
27 days ago
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be access...
Neutral
Seeking Alpha
about one month ago
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Ca...
Neutral
Business Wire
about one month ago
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. “2024 was marked by strong clinical execution and pipeline advancement, highl...
More Silence Therapeutics Plc - ADR News

Company Profile

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Craig Tooman
Employees 116
Founded 1994
Website www.silence-therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today